Opinion
NO. CIV. 06-665 WBS GGH
09-06-2011
CHERYL J. WHITE, SUCCESSOR TO WILLIAM WHITE, Plaintiff, v. NOVARTIS PHARMACEUTICALS CORPORATION, Defendant.
ORDER RE: OBJECTIONS TO FINAL PRETRIAL ORDER
Defendant's exhibit list is amended to reflect that defendant also intends to offer the exhibits identified at Exhibit A to this Order. All other objections (Docket Nos. 176-77.) to the Final Pretrial Order (Docket No. 174) are overruled.
IT IS SO ORDERED.
WILLIAM B. SHUBB
UNITED STATES DISTRICT JUDGE
Exhibit "A": Defendant's Exhibits
+-----------------------------------------------------------------------------+ ¦Ex. ¦Doc. ¦ ¦ ¦ ¦No. ¦ ¦Date ¦Description ¦ ¦ ¦Group ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦6/21/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Petraglia ltr to Padzur ¦ ¦0583 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦6/29/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Weiss eml to Dunsire ¦ ¦0584 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦7/1/ ¦ ¦ ¦ ¦Docs ¦2004 ¦E-mail string re: Discussion with Dr. Buoquot ¦ ¦0585 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦7/7/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Pease e-mail to Miranda ¦ ¦0586 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦7/7/ ¦July 7, 2004 e-mail from Dorothy Pease to Robert ¦ ¦ ¦Docs ¦2004 ¦Miranda with attachment ¦ ¦0587 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦7/9/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Petraglia eml to Pease ¦ ¦0588 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦ ¦ ¦ ¦E-mail from Annmarie Petraglia to Dorothy ¦ ¦DX- ¦Corp ¦7/9/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Pease dated 7/9/04 re: ¦ ¦0589 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa Labeling ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦7/15/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Maladorno e-mail to Bess, Close, Renner ¦ ¦0590 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦8/2/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Staten e-mail to Miranda ¦ ¦0591 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦8/25/ ¦ ¦ ¦ ¦Docs ¦2004 ¦8/04 Zometa Nonclinical Overview ¦ ¦0592 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦9/21/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Dear Doctor Letter MedWatch Submission ¦ ¦0593 ¦ ¦ ¦ ¦ +-----+-------+-------+-------------------------------------------------------¦ ¦DX- ¦Corp ¦9/24/ ¦ ¦ ¦ ¦Docs ¦2004 ¦Dear Doctor Letter with package insert ¦ ¦0594 ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+
+-----------------------------------------------------------------------------+ ¦ ¦Doc.¦ ¦ ¦ ¦Ex. No.¦ ¦Date¦Description ¦ ¦ ¦Grou¦ ¦ ¦ ¦ ¦P ¦ ¦ ¦ +-------+----+----+-----------------------------------------------------------¦ ¦ ¦ ¦ ¦Application to Market a New Drug, Biologic, or an ¦ ¦ ¦ ¦9/24¦Antibiotic Drug for Human Use, Sept. ¦ ¦DX-0595¦Corp¦/ ¦ ¦ ¦ ¦Docs¦2004¦24, 2004 submission ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦re: Zometa with attachments ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦9/29¦Zometa Briefing Book for Renal Safety and Treatment ¦ ¦ ¦Docs¦/ ¦Duration Meeting ¦ ¦0596 ¦ ¦2004¦ ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦10/5¦ ¦ ¦ ¦Docs¦/ ¦Memo from Zometa Brand Team re: Label Change ¦ ¦0597 ¦ ¦2004¦ ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦11/3¦ ¦ ¦ ¦Docs¦/ ¦Final Draft of Briefing Book for Sr Management review ¦ ¦0598 ¦ ¦2004¦ ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦11/ ¦Application to Market a New Drug, Biologic, or an ¦ ¦ ¦Docs¦15/ ¦Antibiotic Drug for Human Use, Nov. 15, 2004 submission re:¦ ¦0599 ¦ ¦2004¦Aredia with attachments ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦11/ ¦Agarwala et al., Efficacy of alendronate, a bisphosphonate,¦ ¦ ¦Docs¦24/ ¦in the treatment of AVN of the hip. A prospective ¦ ¦0600 ¦ ¦2004¦open-label study, Rheumatology 2005;44:352-359 ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦12/1¦ ¦ ¦ ¦Docs¦/ ¦Zometa Brochure ¦ ¦0601 ¦ ¦2004¦ ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦12/1¦ ¦ ¦ ¦Docs¦/ ¦Renner eml to Sablinska ¦ ¦0602 ¦ ¦2004¦ ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦12/ ¦ ¦ ¦ ¦Docs¦23/ ¦Narang eml to Burke ¦ ¦0603 ¦ ¦2004¦ ¦ +-------+----+----+-----------------------------------------------------------¦ ¦DX- ¦Corp¦1/4/¦ ¦ ¦ ¦Docs¦2005¦Petraglia eml to Maladorno ¦ ¦0604 ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+
+------------------------------------------------------------------------------+ ¦ ¦Doc. ¦ ¦ ¦ ¦Ex. No.¦ ¦Date ¦Description ¦ ¦ ¦Grou ¦ ¦ ¦ ¦ ¦P ¦ ¦ ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX- ¦Corp ¦1/11/¦ ¦ ¦ ¦Docs ¦2005 ¦Maladorno eml to Camanis ¦ ¦0605 ¦ ¦ ¦ ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX- ¦Corp ¦1/31/¦ ¦ ¦ ¦Docs ¦2005 ¦Orloff ltr to Petraglia ¦ ¦0606 ¦ ¦ ¦ ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦ ¦ ¦ ¦E-mail from Annmarie Petraglia to Yong Hei and others ¦ ¦DX- ¦ ¦ ¦dated ¦ ¦ ¦Corp ¦1/31/¦ ¦ ¦0607 ¦Docs ¦2005 ¦1/31/05 re: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Teleconference with ODS ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX- ¦Corp ¦1/31/¦ ¦ ¦ ¦Docs ¦2005 ¦Jan. 31, 2005 FDA Approval Letter for Zometa ¦ ¦0608 ¦ ¦ ¦ ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX- ¦Corp ¦2/1/ ¦ ¦ ¦ ¦Docs ¦2005 ¦Zometa Multiple Myeloma Brochure ¦ ¦0609 ¦ ¦ ¦ ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX- ¦Corp ¦2/1/ ¦Reviewer Guidance: Conducting A Clinical Safety Review Of ¦ ¦ ¦Docs ¦2005 ¦A New Product Application And Repairing A Report On The ¦ ¦0610 ¦ ¦ ¦Review, FDA 2005 ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX-0611¦Corp ¦2/1/ ¦ODAC - Background information ¦ ¦ ¦Docs ¦2005 ¦ ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX- ¦Corp ¦2/2/ ¦Feb. 2, 2 005 FDA ¦ ¦ ¦Docs ¦2005 ¦ ¦ ¦0612 ¦ ¦ ¦Supplemental Approval Letter for Aredia ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX- ¦Corp ¦2/9/ ¦E-mail from Kara Kuriger to Thomas Bock and others re: 2/ ¦ ¦ ¦Docs ¦2005 ¦11/05 Ad Board ¦ ¦0613 ¦ ¦ ¦ ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦ ¦ ¦ ¦Feb. 2005 e-mail ¦ ¦DX-0614¦Corp ¦2/13/¦ ¦ ¦ ¦Docs ¦2005 ¦string re: Let's reach a decision on one additional ¦ ¦ ¦ ¦ ¦analysis ¦ +-------+-----+-----+----------------------------------------------------------¦ ¦DX-0615¦Corp ¦2/15/¦Clinical Trial Team Minutes 2/15/05 ¦ ¦ ¦Docs ¦2005 ¦ ¦ +------------------------------------------------------------------------------+
+------------------------------------------------------------------------------+ ¦Ex. ¦Doc. ¦ ¦ ¦ ¦No. ¦ ¦Date ¦Description ¦ ¦ ¦Grou P¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦2/23/ ¦E-mail from Yong Hei to Stephanie Petrone dated 2/23/05 re:¦ ¦ ¦Docs ¦2005 ¦Zometa Protocol Amendment ¦ ¦0616¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦3/1/ ¦FDA Guidance for Industry "Good Pharmacovigilance Practices¦ ¦ ¦Docs ¦2005 ¦and Pharmacoepidemiologic Assessment" ¦ ¦0617¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦3/4/ ¦ ¦ ¦ ¦Docs ¦2005 ¦ODAC report by Sablinska ¦ ¦0618¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦3/4/ ¦ ¦ ¦ ¦Docs ¦2005 ¦Draft ODAC Meeting Slide Presentation ¦ ¦0619¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦3/4/ ¦ ¦ ¦ ¦Docs ¦2005 ¦ODAC Background Information ¦ ¦0620¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦4/6/ ¦Post-ODAC ¦ ¦ ¦Docs ¦2005 ¦ ¦ ¦0621¦ ¦ ¦teleconference minutes ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦4/6/ ¦ ¦ ¦ ¦Docs ¦2005 ¦FDA Teleconference Minutes dated 4/6/05 ¦ ¦0622¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦4/28/ ¦Email forwarding FDA Letter re: 15 day reporting dated 4/22¦ ¦ ¦Docs ¦2005 ¦/05 ¦ ¦0623¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦4/27/ ¦ ¦ ¦ ¦Docs ¦2005 ¦Orloff ltr to Petraglia ¦ ¦0624¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦5/5/ ¦ ¦ ¦ ¦Docs ¦2005 ¦NPC Dear Dentist Letter ¦ ¦0625¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦8/19/ ¦ ¦ ¦ ¦Docs ¦2005 ¦Periodic Safety Report (Draft) ¦ ¦0626¦ ¦ ¦ ¦ +----+------+------+-----------------------------------------------------------¦ ¦DX- ¦Corp ¦10/1/ ¦ ¦ ¦ ¦Docs ¦2005 ¦10/05 CES Appendix, ¦ ¦0627¦ ¦ ¦ ¦ +------------------------------------------------------------------------------+
+-----------------------------------------------------------------------------+ ¦Ex. ¦Doc. ¦ ¦ ¦ ¦No. ¦ ¦Date ¦Description ¦ ¦ ¦Grou P¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦10/12/¦ ¦ ¦ ¦Docs ¦2005 ¦McGrath ltr to FDA ¦ ¦0628 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦10/18/¦ ¦ ¦ ¦Docs ¦2005 ¦PSUR 7 ¦ ¦0629 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦10/28/¦ ¦ ¦ ¦Docs ¦2005 ¦10/05 Zometa Clincial Expert Statement ¦ ¦0630 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦12/7/ ¦ ¦ ¦ ¦Docs ¦2005 ¦Zometa Clinical Expert Statement - Appx. 1 ¦ ¦0631 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦12/7/ ¦ ¦ ¦ ¦Docs ¦2005 ¦Zometa Clinical Expert Statement ¦ ¦0632 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦12/7/ ¦ ¦ ¦ ¦Docs ¦2005 ¦Zometa Clinical Expert Statement - Appx. 1 ¦ ¦0633 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦1/1/ ¦ ¦ ¦ ¦Docs ¦2006 ¦AAOMS ONJ guidelines 2006 ¦ ¦0634 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦2/26/ ¦ ¦ ¦ ¦Docs ¦2006 ¦McGrath eml to Staten ¦ ¦0635 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦5/1/ ¦Updated Rec. for the Prevention, Diagnosis, and Treatment¦ ¦ ¦Docs ¦2006 ¦of ONJ in Patients with Cancer ¦ ¦0636 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦6/21/ ¦ ¦ ¦ ¦Docs ¦2006 ¦Letter to Healthcare Professionals ¦ ¦0637 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦6/21/ ¦ ¦ ¦ ¦Docs ¦2006 ¦Letter to Doctors ¦ ¦0638 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦6/21/ ¦ ¦ ¦ ¦Docs ¦2006 ¦Letter to Patient Advocacy Groups ¦ ¦0639 ¦ ¦ ¦ ¦ +-----+------+------+---------------------------------------------------------¦ ¦DX- ¦Corp ¦9/22/ ¦ ¦ ¦ ¦Docs ¦2006 ¦McGrath ltr to Justice ¦ ¦0640 ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+
+-----------------------------------------------------------------------------+ ¦ ¦Doc. ¦ ¦ ¦ ¦Ex. No.¦ ¦Date ¦Description ¦ ¦ ¦Grou P ¦ ¦ ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX-0641¦Corp Docs¦11/22/2006¦Clinical Study Report, Study No:ZOL446E US 32 ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦8/17/2007 ¦Aredia CES Appendix ¦ ¦0642 ¦ ¦ ¦ ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦Sept. 12, 2007 letter ¦ ¦ ¦CorP Docs¦9/12/2007 ¦ ¦ ¦0643 ¦ ¦ ¦from Lynne McGrath to Mary Parks with ¦ ¦ ¦ ¦ ¦attachments ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX-0644¦Corp Docs¦11/8/2007 ¦FDA ltr to McGrath ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX-0645¦Corp Docs¦ ¦Zometa 2003 MPH Tactics ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦6/16/2004 ¦Field Communication -New Zometa PI ¦ ¦0646 ¦ ¦ ¦ ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦ ¦Osteonecrosis of the Jaw - Slide Deck ¦ ¦0647 ¦ ¦ ¦ ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦ ¦Taking Care of Yourself While Living With Cancer¦ ¦0648 ¦ ¦ ¦ ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦2/1/2005 ¦Zometa Brochure ¦ ¦0649 ¦ ¦ ¦ ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦4/1/2005 ¦Assessment and Management of Bone Metastases ¦ ¦0650 ¦ ¦ ¦ ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX-0651¦Corp Docs¦4/1/2005 ¦To Protect Your Bones ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦10/5/2004 ¦Field Communication -Label Change for Zometa ¦ ¦0652 ¦ ¦ ¦ ¦ +-------+---------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦6/10/2003 ¦Email from Epstein to Ebeling ¦ ¦0653 ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+
+------------------------------------------------------------------------+ ¦ ¦Doc. ¦ ¦ ¦ ¦Ex. No.¦ ¦Date ¦Description ¦ ¦ ¦Grou P ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX-0654¦Corp Docs¦6/25/2004¦Email from Hohneker to Johnson ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX-0655¦Corp Docs¦2/26/2004¦Email from Miranda to Dunsire and others ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦2/25/2004¦Email from Maladorno to Miranda ¦ ¦0656 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦2/27/2004¦Email from Petraglia to Goessl and others ¦ ¦0657 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦2/9/2004 ¦Email from Petraglia to Narang ¦ ¦0658 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦8/4/2004 ¦Email from Petraglia to Miranda ¦ ¦0659 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦ ¦Exhibit 5501 from Petrone 8/21 Deposition ¦ ¦0660 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦5/9/2004 ¦Email from Hei to Ruggiero and others ¦ ¦0661 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦5/11/2004¦Email from Abam to Ruggiero ¦ ¦0662 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦ ¦Draft Epidemiology Report ¦ ¦0663 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦3/4/2005 ¦Appendix 2 -Osteonecrosis in Cancer Patients¦ ¦0664 ¦ ¦ ¦ ¦ +-------+---------+---------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦8/22/1995¦Fax to Macalush from Hedin ¦ ¦0665 ¦ ¦ ¦ ¦ +------------------------------------------------------------------------+
+----------------------------------------------------------------+ ¦ ¦Doc. ¦ ¦ ¦ ¦Ex. No.¦ ¦Date ¦Description ¦ ¦ ¦Grou P ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦Field Communication -Update on ¦ ¦ ¦Corp Docs¦2/3/2005 ¦ ¦ ¦0666 ¦ ¦ ¦Osteonecrosis of the Jaw (ONJ) ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦Field Communication -Update on ¦ ¦ ¦Corp Docs¦2/8/2005 ¦ ¦ ¦0667 ¦ ¦ ¦Osteonecrosis of the Jaw (ONJ) ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦ ¦Zometa Brochure ¦ ¦0668 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦4/15/2005¦Draft Module - Selling Zometa ¦ ¦0669 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦ ¦Slide Deck - Leave No Patient Behind¦ ¦0670 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦2/16/2005¦Field Communication ¦ ¦0671 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦8/10/2005¦Email from Lantwicki to Hei ¦ ¦0672 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦6/10/2005¦Email from Scott to Lantwicki ¦ ¦0673 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦ ¦Exhibit D-12 from Scott Deposition ¦ ¦0674 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦6/21/2005¦Dear Healthcare Professional Letter ¦ ¦0675 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦6/21/2005¦Dear Doctor Letter ¦ ¦0676 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦6/21/2005¦Dear Patient Advocate Letter ¦ ¦0677 ¦ ¦ ¦ ¦ +----------------------------------------------------------------+
+----------------------------------------------------------------------+ ¦ ¦Doc. ¦ ¦ ¦ ¦Ex. No.¦ ¦Date ¦Description ¦ ¦ ¦Grou P ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦3/24/2004¦CV of the Experts -Non-Clinical ¦ ¦0678 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦4/26/2004¦Email from Tarassoff to Dunsire and others¦ ¦0679 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦5/9/2005 ¦Advisory Board Executive Summary ¦ ¦0680 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦ ¦Slide Deck -Osteonecrosis of the Jaw ¦ ¦0681 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦4/28/2004¦NEM Minutes ¦ ¦0682 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦7/15/2004¦NEM Minutes ¦ ¦0683 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦3/1/2004 ¦Zometa Label ¦ ¦0684 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦8/1/2004 ¦Zometa Label ¦ ¦0685 ¦ ¦ ¦ ¦ +-------+---------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Corp Docs¦8/1/2004 ¦Aredia Label ¦ ¦0686 ¦ ¦ ¦ ¦ +----------------------------------------------------------------------+